News Focus
News Focus
Post# of 257263
Next 10
Followers 843
Posts 122805
Boards Moderated 10
Alias Born 09/05/2002

Re: jq1234 post# 107199

Monday, 10/25/2010 7:12:11 PM

Monday, October 25, 2010 7:12:11 PM

Post# of 257263
This is a low-risk undertaking by VRTX/JNJ. Assuming that patient compliance is strong (as it ought to be in an open-label clinical setting where there are no superfluous placebo pills), the only underlying scientific issue is the PK profile of Telaprevir, which by now is well understood. With a typical non-inferiority margin for this kind of study, the likelihood of a non-inferiority finding is very high, IMO.

Any guesses on the quiz question in #msg-55918145?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up